





Chronic Stroke Prevalence: 2025 female Baseline 0.14 Lifestyle Outreach 0.12 Polypill 0.10 0.08 0.06 0.04 0.02 0.00 70\_to\_74 · 75\_to\_79 65\_to\_69 95\_plus 85\_to\_89 25\_to\_29 30\_to\_34 35\_to\_39 40\_to\_44 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 90\_to\_94

Chronic Stroke Prevalence: 2026 female 0.14 Baseline Lifestyle Outreach 0.12 Polypill 0.10 0.08 0.06 0.04 0.02 0.00 40\_to\_44 -70\_to\_74 · 65\_to\_69 85\_to\_89 35\_to\_39 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 95\_plus 25\_to\_29












Chronic Stroke Prevalence: 2031 female Baseline 0.12 Lifestyle Outreach 0.10 Polypill 0.08 0.06 0.04 0.02 0.00 70\_to\_74 -75\_to\_79 65\_to\_69 85\_to\_89 95\_plus 30\_to\_34 35\_to\_39 40\_to\_44 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 90\_to\_94 25\_to\_29


Chronic Stroke Prevalence: 2032 female 0.12 Baseline Lifestyle Outreach 0.10 Polypill 0.08 0.06 0.04 0.02 0.00 45\_to\_49 -65\_to\_69 -70\_to\_74 -75\_to\_79 · 50\_to\_54 85\_to\_89 25\_to\_29 30\_to\_34 35\_to\_39 40\_to\_44 55\_to\_59 60\_to\_64 80\_to\_84 90\_to\_94 95\_plus




Chronic Stroke Prevalence: 2034 female Baseline Lifestyle 0.10 Outreach Polypill 0.08 0.06 0.04 0.02 0.00 45\_to\_49 -65\_to\_69 -70\_to\_74 -75\_to\_79 · 85\_to\_89 25\_to\_29 30\_to\_34 35\_to\_39 40\_to\_44 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 90\_to\_94 95\_plus









Chronic Stroke Prevalence: 2038 female 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 40\_to\_44 · 45\_to\_49 -60\_to\_64 -70\_to\_74 -50\_to\_54 75\_to\_79 65\_to\_69 85\_to\_89 30\_to\_34 35\_to\_39 55\_to\_59 80\_to\_84 90\_to\_94 95\_plus 25\_to\_29






Chronic Stroke Prevalence: 2023 male 0.10 Baseline Lifestyle Outreach Polypill 0.08 0.06 0.04 0.02 0.00 95\_plus -70\_to\_74 -90\_to\_94 -45\_to\_49 50\_to\_54 75\_to\_79 65\_to\_69 85\_to\_89 25\_to\_29 30\_to\_34 35\_to\_39 40\_to\_44 55\_to\_59 60\_to\_64 80\_to\_84



Chronic Stroke Prevalence: 2025 male Baseline Lifestyle Outreach 0.08 Polypill 0.06 0.04 0.02 0.00 40\_to\_44 · 60\_to\_64 -70\_to\_74 -45\_to\_49 50\_to\_54 75\_to\_79 65\_to\_69 30\_to\_34 35\_to\_39 55\_to\_59 80\_to\_84 85\_to\_89 95\_plus 25\_to\_29

Chronic Stroke Prevalence: 2026 male Baseline Lifestyle 0.08 Outreach Polypill 0.06 0.04 0.02 0.00 40\_to\_44 · 60\_to\_64 -70\_to\_74 -45\_to\_49 50\_to\_54 75\_to\_79 65\_to\_69 30\_to\_34 35\_to\_39 55\_to\_59 80\_to\_84 85\_to\_89 90\_to\_94 95\_plus 25\_to\_29



Chronic Stroke Prevalence: 2028 male Baseline Lifestyle 0.08 Outreach Polypill 0.06 0.04 0.02 0.00 40\_to\_44 -60\_to\_64 -70\_to\_74 -45\_to\_49 50\_to\_54 75\_to\_79 65\_to\_69 25\_to\_29 35\_to\_39 55\_to\_59 80\_to\_84 85\_to\_89 95\_plus

Chronic Stroke Prevalence: 2029 male Baseline Lifestyle 0.08 Outreach Polypill 0.06 0.04 0.02 0.00 40\_to\_44 -60\_to\_64 -65\_to\_69 -70\_to\_74 -45\_to\_49 50\_to\_54 75\_to\_79 25\_to\_29 35\_to\_39 55\_to\_59 80\_to\_84 85\_to\_89 95\_plus

Chronic Stroke Prevalence: 2030 male Baseline 0.08 Lifestyle Outreach 0.07 Polypill 0.06 0.05 0.04 0.03 0.02 0.01 0.00 70\_to\_74 -75\_to\_79 65\_to\_69 85\_to\_89 95\_plus 25\_to\_29 30\_to\_34 35\_to\_39 40\_to\_44 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 90\_to\_94

Chronic Stroke Prevalence: 2031 male 0.08 Baseline Lifestyle Outreach 0.07 Polypill 0.06 0.05 0.04 0.03 0.02 0.01 0.00 45\_to\_49 · 70\_to\_74 -75\_to\_79 95\_plus 55\_to\_59 65\_to\_69 85\_to\_89 30\_to\_34 35\_to\_39 40\_to\_44 50\_to\_54 60\_to\_64 80\_to\_84 90\_to\_94 25\_to\_29

Chronic Stroke Prevalence: 2032 male 0.08 Baseline Lifestyle 0.07 Outreach Polypill 0.06 0.05 0.04 0.03 0.02 0.01 0.00 45\_to\_49 · 70\_to\_74 · 90\_to\_94 -65\_to\_69 85\_to\_89 95\_plus 30\_to\_34 35\_to\_39 40\_to\_44 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 25\_to\_29

Chronic Stroke Prevalence: 2033 male Baseline Lifestyle 0.07 Outreach Polypill 0.06 0.05 0.04 0.03 0.02 0.01 0.00 95\_plus -70\_to\_74 -75\_to\_79 65\_to\_69 85\_to\_89 30\_to\_34 35\_to\_39 40\_to\_44 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 90\_to\_94 25\_to\_29

Chronic Stroke Prevalence: 2034 male Baseline 0.07 Lifestyle Outreach Polypill 0.06 0.05 0.04 0.03 0.02 0.01 0.00 70\_to\_74 · 75\_to\_79 65\_to\_69 85\_to\_89 95\_plus 25\_to\_29 30\_to\_34 35\_to\_39 40\_to\_44 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 90\_to\_94

Chronic Stroke Prevalence: 2035 male Baseline 0.07 Lifestyle Outreach Polypill 0.06 0.05 0.04 0.03 0.02 0.01 0.00 70\_to\_74 -75\_to\_79 65\_to\_69 85\_to\_89 95\_plus 25\_to\_29 30\_to\_34 35\_to\_39 40\_to\_44 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 90\_to\_94

Chronic Stroke Prevalence: 2036 male Baseline 0.07 Lifestyle Outreach Polypill 0.06 0.05 0.04 0.03 0.02 0.01 0.00 70\_to\_74 -75\_to\_79 65\_to\_69 85\_to\_89 95\_plus 25\_to\_29 30\_to\_34 35\_to\_39 40\_to\_44 45\_to\_49 50\_to\_54 55\_to\_59 60\_to\_64 80\_to\_84 90\_to\_94

Chronic Stroke Prevalence: 2037 male Baseline 0.07 Lifestyle Outreach 0.06 Polypill 0.05 0.04 0.03 0.02 0.01 0.00 95\_plus -70\_to\_74 -75\_to\_79 -65\_to\_69 55\_to\_59 85\_to\_89 90\_to\_94 25\_to\_29 30\_to\_34 35\_to\_39 40\_to\_44 45\_to\_49 50\_to\_54 60\_to\_64 80\_to\_84

Chronic Stroke Prevalence: 2038 male 0.07 Baseline Lifestyle 0.06 Outreach Polypill 0.05 0.04 0.03 0.02 0.01 0.00 95\_plus -45\_to\_49 -70\_to\_74 -75\_to\_79 -65\_to\_69 40\_to\_44 55\_to\_59 85\_to\_89 90\_to\_94 25\_to\_29 30\_to\_34 35\_to\_39 50\_to\_54 60\_to\_64 80\_to\_84

